12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Imeglimin: Phase II data

A Phase II trial in 150 patients inadequately controlled by Januvia sitagliptin showed that oral imeglimin as an add-on to Januvia met the primary endpoint of reducing HbA1c from baseline to week 12...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >